Hishida, Tomoyuki

写真a

Affiliation

School of Medicine, Department of Surgery (General Thoracic Surgery) (Shinanomachi)

Position

Associate Professor

External Links

Career 【 Display / hide

  • 1998.04
    -
    2000.05

    社会保険中京病院, 臨床研修医

  • 2000.06
    -
    2003.05

    国立がんセンター中央病院, 外科, レジデント

  • 2003.06
    -
    2005.05

    国立がんセンター東病院, 呼吸器外科, がん専門修練医

  • 2005.06
    -
    2007.03

    国立がんセンター研究所, 生物学部, リサーチレジデント

  • 2007.04
    -
    2007.07

    名古屋大学医学部, 胸部外科, 研究生

display all >>

Academic Background 【 Display / hide

  • 1998.03

    名古屋大学医学部

    日本, University, Graduated

Academic Degrees 【 Display / hide

  • 医学博士, 名古屋大学, 2007.04

Licenses and Qualifications 【 Display / hide

  • 医師免許, 1998.05

  • ECFMG certificate, 1999

  • 日本外科学会 外科認定医, 2003.12

  • 日本外科学会 外科専門医, 2006.12

  • 日本外科学会 外科指導医, 2016.01

display all >>

 

Research Areas 【 Display / hide

  • Respiratory surgery

Research Keywords 【 Display / hide

  • 胸部悪性腫瘍の外科治療

 

Papers 【 Display / hide

  • A case of solitary pulmonary metastasis from thymoma resected 19 years after surgery

    Suzuki M., Kaseda K., Masai K., Asakura K., Hishida T., Hayashi Y., Asamura H.

    Japanese Journal of Lung Cancer (Japanese Journal of Lung Cancer)  60 ( 5 ) 401 - 406 2020.10

    ISSN  03869628

     View Summary

    © 2020 The Japan Lung Cancer Society. Background. Thymoma is a low-grade malignant epithelial tumor arising in the thymus and rarely metastasizes to distant sites after complete resection. We herein report a rare case of solitary pulmonary metastasis of type Bl thymoma. Case. A woman in her 70s underwent thymectomy with partial resection of the pericardium and right upper lobe for type Bl thymoma 19 years ago. The pathological stage was T3N0M0 Stage III with invasion to the right lung. She received postoperative radiotherapy of 50 Gy with 25 Fr and had no evidence of recurrence until the detection of a 0.8-cm solitary pulmonary nodule in the right lower lobe on follow-up computed tomography (CT) performed 13 years after surgery. The pulmonary nodule gradually grew over the next seven-year follow-up, so we performed wedge resection of the right lower lobe for the diagnosis and treatment. Pathologically, the nodule consisted of epithelial cells with slightly large nuclei and inconspicuous atypia surrounded by a lot of lymphocytes. Immunohistochemically, the epithelial cells were positive for AE1/AE3 and CK19, while the lymphocytes were positive for CD3 and TdT. These findings were similar to those shown in the initial thymoma specimen, and the diagnosis of pulmonary metastasis of type Bl thymoma was made. The patient is doing well 23 months after pulmonary metastasectomy with no evidence of re-recurrence of thymoma. Conclusion. We herein report a resected case of slow-growing pulmonary metastasis from type Bl thymoma with a review of the literature. In cases of type A-Bl thymoma, we should consider the possibility of late recurrence and perform long-term follow-up.

  • First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

    Jia Z., Wang Y., Cao L., Wang Y., Song Y., Yang X., Bing Z., Cao Z., Liu P., Zhang S., Chen Z., Huang M., Yu Y., Han-Zhang H., Song J., Christoph D.C., Passaro A., Gridelli C., Hishida T., Liang N., Li S.

    Journal of Thoracic Disease (Journal of Thoracic Disease)  12 ( 7 ) 3764 - 3773 2020.07

    ISSN  20721439

  • Clinicopathological and prognostic features of operable non-small cell lung cancer patients with diabetes mellitus

    Kaseda K., Hishida T., Masai K., Asakura K., Hayashi Y., Asamura H.

    Journal of Surgical Oncology (Journal of Surgical Oncology)   2020

    ISSN  00224790

     View Summary

    © 2020 Wiley Periodicals LLC Background: The aim of this study was to investigate the clinicopathological and prognostic features of operable non-small cell lung cancer (NSCLC) patients with diabetes mellitus (DM). Methods: A total of 1231 surgically resected NSCLC patients were retrospectively reviewed. Clinicopathological characteristics were compared between patients with DM (DM group, n = 139) and those without DM (non-DM group, n = 1092). The clinical factors associated with postoperative complications and prognostic factors were identified. Results: The DM group had distinct clinicopathological features. No significant differences in histological invasiveness or stage were found. The presence and control status of DM were independent predictors of postoperative complications. No significant differences in recurrence-free survival or cancer-specific survival were observed; however, the DM group had worse overall survival (OS). The DM group had a higher number of deaths from other diseases than the non-DM group, and these patients had significantly higher postoperative hemoglobin A1c levels than patients with cancer-related death. Conclusion: The presence and control status of preoperative DM are useful predictors of both postoperative complications and OS in operable NSCLC patients. Concomitant diabetes-related complications have a negative effect on long-term survival in diabetic NSCLC patients, and long-term glycemic control is important to prolong OS.

  • Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: Real-world data from Japan

    Yoh K., Takamochi K., Shukuya T., Hishida T., Tsuboi M., Sakurai H., Goto Y., Yoshida K., Ohde Y., Okumura S., Ohashi Y., Kunitoh H.

    Japanese Journal of Clinical Oncology (Japanese Journal of Clinical Oncology)  49 ( 1 ) 63 - 68 2019

    ISSN  03682811

     View Summary

    © The Author(s) 2018. Published by Oxford University Press. All rights reserved. Background: Adjuvant tegafur/uracil (UFT) chemotherapy is recommended for patients with completely resected Stage I non-small cell lung cancer (NSCLC) in Japan. A Phase III trial, the Japan Clinical Oncology Group (JCOG) 0707, comparing the survival benefit of UFT and S-1 (tegafur/gimeracil/oteracil) for this population is being conducted. However, the selection of patients in the randomized clinical trial (RCT) may not represent the real-world population. The present study aimed to investigate the pattern of care for patients receiving adjuvant chemotherapy for completely resected NSCLC. Methods: Patients with completely resected pathological Stage I (T1 > 2 cm and T2 in 6th TNM edition) NSCLC eligible for the JCOG0707 trial but excluded from it during the enrollment period (2008–13) were eligible for this study. Physicians from institutions that participated in the JCOG0707 retrospectively assessed the medical records of each patient. Results: This study enrolled 5006 patients, 85% of those initially considered for participation in the JCOG0707 trial (5006 of 5923 patients). Among them, 2389 were ineligible for the trial and 2617 had not been enrolled despite being eligible. The most frequent reason for non-enrollment despite eligibility was the decline in patients’ participation, and the major reasons for trial ineligibility were concomitant malignancy and comorbidities. Of all the patients enrolled in our study, 1659 received adjuvant chemotherapy, mainly UFT. Conclusions: Our study indicates that only 15% of the real-world patients with completely resected NSCLC were enrolled into the adjuvant chemotherapy RCT, and among those not participating in the trial, one-third received adjuvant chemotherapy.

  • Survival and prognostic factors after pulmonary metastasectomy of head and neck cancer: What are the clinically informative prognostic indicators?

    Oki T., Hishida T., Yoshida J., Goto M., Sekihara K., Miyoshi T., Aokage K., Ishii G., Tsuboi M.

    European Journal of Cardio-thoracic Surgery (European Journal of Cardio-thoracic Surgery)  55 ( 5 ) 942 - 947 2019

    ISSN  10107940

     View Summary

    © 2018 The Author(s). Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. OBJECTIVES: The purpose of this study was to elucidate the surgical outcomes and identify the prognostic factors after pulmonary metastasectomy for head and neck cancer (HNC) using a recent, large, single-institutional cohort. METHODS: We retrospectively reviewed the clinicopathological profiles of 77 consecutive patients who underwent metastasectomy for pulmonary metastases (PMs) arising due to HNC from 1992 to 2013. The prognostic factors associated with overall survival (OS) after pulmonary metastasectomy were evaluated using the univariable and multivariable Cox proportional hazard models. The cut-off value of continuous variables was determined by a receiver operating characteristic analysis. RESULTS: The most predominant histology was squamous cell carcinoma (75%). The median disease-free interval between the treatment of primary HNC and the diagnosis of PMs was 17 months. Recurrence before lung metastasectomy was observed in 32% of patients. The median size of the PM was 2.2 cm. The median survival time after lung metastasectomy was 66 months, and the 5-year OS was 54%. In the multivariable analysis, squamous cell histology [hazard ratio (HR) 2.92, 95% confidence interval (CI) 1.00-8.57], disease-free interval (<18 months, HR 3.23, 95% CI 1.49-7.02), recurrence before lung metastasis (HR 2.39, 95% CI 1.19-4.80) and size of the PM (>2.5 cm, HR 2.75, 95% CI 1.33-5.69) were independent predictors of a poor prognosis. The OS of patients with 3 or more factors was significantly worse than that of patients with 2 or less factors (3-year OS 20% vs 83%, P < 0.01). CONCLUSIONS: Surgical resection of PMs from HNC can achieve favourable survival in a selected population. The number of prognostic factors may be useful information for determining the surgical indications and for predicting survival for PMs from HNC.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

Presentations 【 Display / hide

  • 大腸癌再発肺転移に対する反復切除の意義-反復切除は再び治癒の可能性を与えうるのか?-

    HISHIDA Tomoyuki

    第79回日本臨床外科学会総会, 2017.11, Symposium, Workshop, Panelist (nomination)

  • 原発性肺癌に対する至適なリンパ節郭清とは-臨床試験とその先-

    HISHIDA Tomoyuki

    第79回日本臨床外科学会総会, 2017.11, Symposium, Workshop, Panelist (nomination)

  • 分子標的治療を受けた進行肺癌の残存/増悪原発巣に対するsalvage surgery

    HISHIDA Tomoyuki

    第33回日本呼吸器外科学会総会, 2016.05, Symposium, Workshop, Panelist (public offering)

  • 胸腺癌に対する外科治療の長期予後と予後因子:日本胸腺研究会多施設研究306例の解析

    HISHIDA Tomoyuki

    第35回日本胸腺研究会, 2016.02, Symposium, Workshop, Panelist (nomination)

  • Does Repeat Lung Resection Provide a Chance of Cure for Recurrent Pulmonary Metastases of Colorectal Cancer? Results of a Retrospective Japanese Multicenter Study

    HISHIDA Tomoyuki

    52nd Annual Meeting, Society of Thoracic Surgeons (STS), Phoenix, AZ, USA, 2016.01, Poster (general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 臨床病期Ⅰ/Ⅱ期非小細胞肺癌におけるリンパ節郭清の縮小化の治療的意義を検証するランダム化比較試験

    2020.04
    -
    Present

    日本医療研究開発機構 (AMED), 革新的がん医療実用化研究事業, Research grant, Co-investigator

  • 臨床病期I/II期非小細胞肺癌におけるリンパ節郭清の縮小化の治療的意義を 検証するランダム化比較試験

    2017.04
    -
    2020.03

    日本医療研究開発機構 (AMED), 革新的がん医療実用化研究事業, Research grant, Co-investigator

  • 難治組織肺癌である肺多形癌の病態解明・治療開発を目指した分子病理学的研究

    2016.04
    -
    2019.03

    Grant-in-Aid for Scientific Research, Principal Investigator

  • ALK融合遺伝子陽性のIII期非小細胞肺癌に対する集学的治療法の開発に関する研究

    2014.04
    -
    2015.03

    Health and Labour Sciences Research Grants, Co-investigator

  • 肺大細胞神経内分泌癌におけるがん幹細胞の同定と機能解析

    2012.04
    -
    2014.03

    Grant-in-Aid for Scientific Research, Principal Investigator

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, SURGERY

    2021

  • CLINICAL CLERKSHIP IN THORACIC SURGERY

    2021

  • LECTURE SERIES, SURGERY

    2020

  • CLINICAL CLERKSHIP IN THORACIC SURGERY

    2020

  • LECTURE SERIES, SURGERY

    2019

 

Memberships in Academic Societies 【 Display / hide

  • 日本外科学会

     
  • 日本胸部外科学会

     
  • 日本呼吸器外科学会

     
  • 日本呼吸器内視鏡学会

     
  • 日本肺癌学会

     

display all >>

Committee Experiences 【 Display / hide

  • 2020
    -
    Present

    手術記載検討委員会 副委員長, 日本肺癌学会

  • 2019.04
    -
    Present

    プロトコール審査委員会委員, 日本臨床腫瘍研究グループ(JCOG)

  • 2013.05
    -
    Present

    評議員, 日本呼吸器外科学会

  • 2013.05
    -
    Present

    編集委員, 日本呼吸器外科学会

  • 2018
    -
    Present

    胸腔鏡安全技術認定制度検討部会 実務委員会委員, 日本呼吸器外科学会

display all >>